Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Blood Test with Potential to Detect Stage One Cancer

Published: Tuesday, October 23, 2012
Last Updated: Tuesday, October 23, 2012
Bookmark and Share
Soricimed Biopharma Inc. announced that a pre-regulatory study of their blood test for early detection and diagnosis of cancer has commenced.

Soricimed developed their blood test to detect the presence of TRPV6 messenger RNA, a biomarker identified as being present in many epithelially derived cancers. The test has been shown to detect a host of cancers, including ovarian, breast and prostate, at their earliest stages.

Working in partnership with the Dr. Georges-L.-Dumont University Hospital Centre, a member institution of the Vitalite Health Network, located in Moncton, NB, Soricimed has initiated a blood sampling project to collect samples from up to 700 patients.

"We have been able to isolate a marker from human blood plasma which, in cancer patients, shows a fingerprint of the cancer", commented Professor Jack Stewart, Chief Scientific Officer at Soricimed Biopharma. "It's like an early warning system that alerts physicians to the presence of cancer."

"Half the battle with cancer is being able to detect it early enough to save lives", stated Elisabeth Ross, Chief Executive Officer, Ovarian Cancer Canada. "In the case of ovarian cancer, there are no early symptoms and currently no screening tests available so it's not usually detected until Stage Three or Four. As a result, the mortality rate is extremely high, with - 70% of women not surviving more than five years. If ovarian cancer could be detected at Stage One, we could dramatically increase survival rates."

"We are thrilled to be part of the research continuum that moves novel discoveries into the clinical practice, in hopes of improving the health outcomes of our population. The success of this project is the result of a great collaboration with Soricimed Biopharma Inc., our clinicians and multidisciplinary teams at the Dr. Georges-L.-Dumont University Hospital Centre", stated Gilles Beaulieu, Vice-President, Academic Affairs and Research at Vitalite Health Network.

The study is expected to be completed late Fall of this year. Based on successful results, Soricimed Biopharma would move the test through the regulatory approval process which could result in an approved diagnostic being available for use within 24 months. Testing for cancer could become just another box to check on a person's regular physical examination.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Cancer Related Immune Response Genes Uncovered
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Virus Inspired Cell Cargo Ships
Virus-inspired container design may lead to cell cargo ships following construction of ten large, two-component, icosahedral protein complexes.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!